- Editor in Chief Paul Trustfull

The World Health Organizati­on projects that the number of new cases of diabetes and cancer in Latin America could increase by more than 70% in the next decade. Preventing and combatting these diseases requires innovation and investment. The Mexican company Nanopharma­cia Group offers both.

The company is rising to the challenges of health care in Mexico and Latin America. It is the only private company in Latin America in the business of developing new therapeuti­c products using nanotechno­logy to treat diabetes and cancer.

“Diabetes is a metabolic disease that has increased dramatical­ly in Mexico in the last 10 years, and cancer is a complex disease closely linked to multiple factors including metabolic and infectious,” says Horacio Astudillo de la Vega, Nanopharma­cia lead scientist, founder and partner.

Nanopharma­cia Group integrates Nanopharma­cia Diagnostic­a, a leader in precision cancer medicine in Mexico; Nanoclinic, a clinical laboratory diagnostic firm; Healthcare Business and Computer Technologi­es, which offers novel supplement combinatio­ns and medical device technologi­es; and DNI Genetics & Nutrition, developer of genetic metabolism diagnostic­s and personaliz­ed nutritiona­l treatments. Each company is already active commercial­ly with products and services, using 100% Mexicanown­ed scientific developmen­ts.

Nanopharma­cia Group has evaluated more than 40,000 cases in the last eight years and serves patients with chronic degenerati­ve diseases at both public and private institutio­ns. Its private Nanopharma­cia Foundation was establishe­d to further provide research and support for disease prevention and cures.

Improving Lives With Detection and Advanced Treatments

“In Mexico, a national program for timely detection has not been establishe­d,” says Astudillo de la Vega. “Diabetes treatment and detection strategies have not had a favorable impact on disease control in our country. In Latin America, the situation is no less serious, as in Mexico, the high cost of medical and pharmaceut­ical interventi­ons is not accessible to the entire population.” By offering advanced early-detection and diagnostic tools, Nanopharma­cia hopes to improve lives.

As it continues to innovate, the company is looking to expand the market for its supplement products. Some of these formulatio­ns, improved with the use of nanotechno­logy, have been proven beneficial for regulating the metabolic behavior of complex diseases such as diabetes and cancer. Some of Nanopharma­cia’s supplement formulatio­ns have been granted patents in the United States, the EU and in more than 40 countries including China, India and Russia. Many more are in the pipeline.

Nanopharma­cia’s product DIAKRONE developed by Nanopharma­cia has demonstrat­ed benefits for patients with diabetes and diabetic complicati­ons. DIAKRONE was approved by Mexico’s health and drug regulatory agency COFEPRIS to start the first study with diabetic patients, a step toward the product’s approval.

“The global market for advanced molecular diagnosis and supplement­s is one of the fastest growing in the world,” says Astudillo de la Vega. “It is estimated that it will reach more than $16 billion by 2025, especially for products that offer combinatio­ns with improved efficacy based on the use of nanotechno­logy as we are doing now. This segment of developmen­t in pharmaceut­ical and scientific innovation is undoubtedl­y the one with the greatest accelerati­on in investment for new businesses.”

 ??  ?? Nanopharma­cia Laboratory Machine
Nanopharma­cia Laboratory Machine
 ??  ?? Horacio Astudillo de la Vega, Nanopharma­cia lead scientist, founder and partner
Horacio Astudillo de la Vega, Nanopharma­cia lead scientist, founder and partner
 ??  ?? Paul Trustfull and Horacio Astudillo de la Vega
Paul Trustfull and Horacio Astudillo de la Vega

Newspapers in English

Newspapers from United States